Press Releases

Press Releases

Date Title  
May 09, 2023 Omeros Corporation Reports First Quarter 2023 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
May 04, 2023 Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
SEATTLE --(BUSINESS WIRE)--May 4, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023 , on Tuesday, May 9, 2023 , after the market closes. Omeros management will host a conference call and
Apr 25, 2023 Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an increase in
Apr 10, 2023 Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
–   Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder – SEATTLE --(BUSINESS WIRE)--Apr. 10, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National
Mar 13, 2023 Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2023-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
Mar 10, 2023 Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
SEATTLE --(BUSINESS WIRE)--Mar. 10, 2023-- Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank . Omeros previously maintained a line of credit with Silicon Valley Bank , which the company
Mar 07, 2023 Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
SEATTLE --(BUSINESS WIRE)--Mar. 7, 2023-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022 , on Monday, March 13, 2023 , after the market closes.
Feb 06, 2023 Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
– OMIDRIA ® -Related Payment Expected to Provide Operating Capital into at Least 2025 – SEATTLE --(BUSINESS WIRE)--Feb. 6, 2023-- Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset